Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...

Award recipients to receive in-kind technologies and services to accelerate therapeutics to market Merck experts to provide ...

Award recipients to receive in-kind technologies and services to accelerate therapeutics to market <li /> Merck e ...

In a 14-1 vote, the panel moved to expand its usage recommendation for both Pfizer’s Prevnar 20 and Merck’s Capvaxive to include all adults aged 50 and older as well as adults between 19 and ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab, marketed ...

The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. And the company has refused to update the language.

BusinessWire India Dar es Salaam [Tanzania] Mumbai Maharashtra [India] October 30 Merck Foundation the philanthropic arm of ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...